Co-Diagnostics, Inc. to Conduct Product Training Seminars with Distributor and Customers in the Dominican Republic

Trainings will be conducted for staff and customers of
Laboratorios Franja, followed by launch of Company’s products in DR

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics
company with a unique, patented platform for the development of
molecular diagnostic tests, announced today that Company distributor in
the Dominican Republic, Laboratorios Franja, will be hosting training
seminars for its customers and sales trainings for its staff in advance
of launching the Company’s products throughout that country.

Co-Diagnostics recently selected Laboratorios Franja S.R.L. as the
exclusive distributor of its diagnostics and Research Use Only (RUO)
products throughout the Dominican Republic, a country of nearly 12
million people. The Company expects the initial product launch to
include the CE-IVD Logix Smart™ tests for tuberculosis and Zika, other
RUO products according to customer demand, and distribution of the CoDx
Box™, a magnetic induction thermocycler with software optimized to run
the Company’s polymerase chain reaction (PCR) products. Laboratorios
Franja, an ISO 9001:2015 certified company, has also agreed to assist
the Company with all local registration requirements needed to allow
import and sale of its products in the Dominican Republic.

Mr. Cameron Gundry, Co-Diagnostics Director of Commercialization for
Latin America, commented, “We are pleased with the progress made so far
by Laboratorios Franja in generating interest for our products in the
Dominican Republic, and completing the necessary registration steps for
our products and company. We look forward to the valuable opportunities
that this relationship creates for both parties, as well as the economic
benefits of participating in the development and expansion of PCR
technology across the Dominican Republic market.

Our official product launch into the Dominican Republic is a significant
step for the commercialization of our company’s products, and one that
shows our ability to build on the momentum we have been creating over
the past several months. Our dedicated sales team continues to add to
our distributor network worldwide in anticipation of following the same
model in other countries that is now being implemented in the Dominican
Republic, and those markets will be notified as similar training
seminars and product demonstrations are scheduled.”

The training seminars will showcase demonstrations of the Company’s PCR
products. They will be conducted by Company representatives and are
scheduled to occur on November 27-28 at Laboratorios Franja’s
headquarters in Santo Domingo, Dominican Republic with up to 20
laboratories and hospitals. Attendance is by invitation only. To request
an invitation, contact the Company using the information at the bottom
of this release, or Laboratorios Franja at info@laboratoriosfranja.com.

About Laboratorios Franja S.R.L.:

Laboratorios Franja is one of the most complete and efficient
microbiology laboratories in Santo Domingo, offering distribution and
sales of microbiology chemistry (cosmetics, medical equipment and
cleaning) products, and food quality/safety, environmental microbiology
and physical water chemistry analyses. Laboratorios Franja also markets
and distributes high quality culture media, and related state-of-the-art
technology. Owned and operated by Frank Reyes, the distributor has a
highly qualified team of medical, lab staff and sales staff, and can be
found online at www.laboratoriosfranja.com.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics
company with a proprietary diagnostic testing technology and development
platform that intends to manufacture and sell reagents used for
diagnostic tests that function via the detection and/or analysis of
nucleic acid molecules (DNA or RNA), and license the use of its platform
to other non-competing developers.

Forward-Looking Statements:

This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
“believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will”
and similar expressions, or the negative of these words. Such
forward-looking statements are based on facts and conditions as they
exist at the time such statements are made and predictions as to future
facts and conditions. Forward-looking statements in this release
include statements regarding the (i) use of funding proceeds, (ii)
expansion of product distribution, (iii) acceleration of initiatives in
liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in the
near-term, (vii) flexibility in managing the Company’s balance sheet,
(viii) anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements are
subject to inherent uncertainties, risks and changes in circumstances.
Actual results may differ materially from those contemplated or
anticipated by such forward-looking statements. Readers of this press
release are cautioned not to place undue reliance on any forward-looking
statements. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this press
release, except as may be required by applicable securities laws.

Contacts

Company Contact:
Denny Crockett
Co-Diagnostics Sales
Representative
801-438-1036
d.crockett@codiagnostics.com

Investor Contact:
Joe Diaz, Robert Blum and Joe Dorame
Lytham
Partners, LLC
602-889-9700
codx@lythampartners.com